Transforming growth factor-β mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells

American Journal of Pathology

Volumn 162, Issue 2, 2003, Pages 597-608

  Beck, Paul L ^a,b   Rosenberg, Ian M ^b   Xavier, Ramnik J ^b   Koh, Theodore ^b   Wong, Josée F ^a,b   Podolsky, Daniel K ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; FATTY ACID BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL MIGRATION; CELL PROLIFERATION; COLITIS; COLON INJURY; CONTROLLED STUDY; ENTERITIS; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TUMOR; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; SURVIVAL; TRANSGENIC MOUSE; WOUND HEALING;

EID: 0037331535     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63853-9     Document Type: Article

References (38)

1. Chen RH, Derynck R: Homomeric interactions between type II transforming growth factor-beta receptors. J Biol Chem 1994, 269:22868-22874
2. Derynck R, Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1997, 1333:F105-F150
3. Zhao Y, Young SL: Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth inhibition. J Biol Chem 1996, 271:2369-2372
4. Wahl SM: Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med 1994, 180:1587-1590
5. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699
6. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774
7. Ciacci C, Lind SE, Podolsky DK: Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology 1993, 105:93-101
8. Dignass AU, Podolsky DK: Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 1993, 105:1323-1332
9. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M: Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 1997, 18:61-64
10. Akiyama Y, Iwanaga R, Saitoh K, Shiba K, Ushio K, Ikeda E, Iwama T, Nomizu T, Yuasa Y: Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 1997, 112:33-39
11. Souza RF, Lei J, Yin J, Appel R, Zou TT, Zhou X, Wang S, Rhyu MG, Cymes K, Chan O, Park WS, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Simms L, Leggett B, Young J, Harpaz N, Meltzer SJ: A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 1997, 112:40-45
12. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Wilson JK: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338
13. Border WA, Noble NA: Fibrosis linked to TGF-beta in yet another disease. J Clin Invest 1995, 96:655-656
14. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360:361-364
15. Graham MF, Bryson GR, Diegelmann RF: Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells. Gastroenterology 1990, 99:447-453
16. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992. 68:775-785
17. Wieser R, Wrana JL, Massague J: GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 1995, 14:2199-2208
18. Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, Roop DR: Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci USA 1997, 94:2386-2391
19. Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, Moses HL: Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997, 139:541-552
20. Simon TC, Cho A, Tso P, Gordon JI: Suppressor and activator functions mediated by a repeated heptad sequence in the liver fatty acid-binding protein gene (Fabpl). Effects on renal, small intestinal, and colonic epithelial cell gene expression in transgenic mice. J Biol Chem 1997, 272:10652-10663
21. Sweetser DA, Hauft SM, Hoppe PC, Birkenmeier EH, Gordon JI: Transgenic mice containing intestinal fatty acid-binding protein-human growth hormone fusion genes exhibit correct regional and cell-specific expression of the reporter gene in their small intestine. Proc Natl Acad Sci USA 1988, 85:9611-9615
22. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803
23. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, Wallace JL: Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998, 62:367-373
24. Koh TJ, Dockray GJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Wang TC: Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. J Clin Invest 1999, 103:1119-1126
25. Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T, Kuziel WA, Maeda N, MacDermott RP, Podolsky DK, Reinecker HC: Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1 + lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000, 164:6303-6312
26. Rubin DC, Ong DE, Gordon JI: Cellular differentiation in the emerging fetal rat small intestinal epithelium: mosaic patterns of gene expression. Proc Natl Acad Sci USA 1989, 86:1278-1282
27. Rubin DC, Roth KA, Birkenmeier EH, Gordon JI: Epithelial cell differentiation in normal and transgenic mouse intestinal isografts. J Cell Biol 1991, 113:1183-1192
28. Beck PL, Podolsky DK: Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999, 5:44-60
29. Babyatsky MW, Rossiter G, Podolsky DK: Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996, 110:975-984
30. Giladi E, Raz E, Karmeli F, Okon E, Rachmilewitz D: Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol 1995, 7:341-347
31. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT: Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001, 108:601-609
32. Fiocchi C: TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001, 108:523-526
33. Mikhailowski R, Shpitz B, Polak-Charcon S, Kost Y, Segal Y, Segal C, Fich A, Lamprecht SA: Controlled release of TGF-beta1 impedes rat colon carcinogenesis in vivo. Int J Cancer 1998, 78:618-623
34. MacKay SL, Auffenberg T, Tannahill CL, Ksontini R, Josephs MD-,Nowak M, Moldawer LL, Copeland III EM: Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype. Ann Surg 1998, 227:781-789
35. Zhu Y, Richardson JA, Parada LF, Graff JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998, 94:703-714
36. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999, 18:1280-1291
37. Hahm KB, Im YH, Parks TW, Park SH, Markowitz S, Jung HY, Green J, Kim SJ: Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001, 49:190-198
38. Itoh H, Beck PL, Inoue N, Xavier R, Podolsky DK: A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest 1999, 104:1539-1547